Patents by Inventor John Michael Morin

John Michael Morin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclopenta[b]indole derivatives as sPLAinhibitors
    Patent number: 7160909
    Abstract: A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: January 9, 2007
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • MCH receptor antagonists
    Patent number: 7132456
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases
    Type: Grant
    Filed: December 3, 2003
    Date of Patent: November 7, 2006
    Assignee: Eli Lilly and Company
    Inventors: James Ronald Gillig, Lawrence Joseph Heinz, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Nancy June Snyder
  • sPLA2 inhibitors
    Patent number: 6974831
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 13, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • sPLA2 inhibitors
    Patent number: 6930123
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: August 16, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Cyclohept'b!indole derivatives as spla2 inhibitors
    Publication number: 20040198801
    Abstract: 1
    Type: Application
    Filed: January 15, 2004
    Publication date: October 7, 2004
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • Compounds and methods for inhibition of HIV and related viruses
    Publication number: 20040116418
    Abstract: The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.
    Type: Application
    Filed: December 1, 2003
    Publication date: June 17, 2004
    Applicant: Medivir AB
    Inventors: Peter Thomas Lind, Rolf Noreen, John Michael Morin, Robert John Ternansky
  • Novel spla2 inhibitors
    Publication number: 20040077704
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 22, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040063967
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040063941
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
  • spla2 inhibitors
    Patent number: 6713505
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett
  • Spla2 inhibitors
    Publication number: 20040059130
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: March 25, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20030236232
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 25, 2003
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett
  • Glycoprotein IIb/IIIa antagonists
    Publication number: 20030135045
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: October 28, 2002
    Publication date: July 17, 2003
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, John Michael Morin, Daniel J. Sall, Marshall A. Skelton, Robert Theodore Vasileff
  • Glycoprotein llb/llla antagonists
    Publication number: 20030130342
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: September 9, 2002
    Publication date: July 10, 2003
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Michael Paal, Gerd Ruhter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Compounds and methods for inhibition of HIV and related viruses
    Publication number: 20020132794
    Abstract: The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.
    Type: Application
    Filed: February 13, 2002
    Publication date: September 19, 2002
    Applicant: MEDIVIR AB
    Inventors: Peter Thomas Lind, Rolf Noreen, John Michael Morin, Robert John Ternansky
  • Compounds and methods for inhibition of HIV and related viruses
    Patent number: 6376492
    Abstract: The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.
    Type: Grant
    Filed: May 9, 2000
    Date of Patent: April 23, 2002
    Assignee: Medivir AB
    Inventors: Peter Thomas Lind, Rolf Noréen, John Michael Morin, Robert John Ternansky
  • sPLA2 inhibitor ester
    Patent number: 6274578
    Abstract: The compound, ((3(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid N-morpholino ester, is disclosed together with its use as a highly bioavailable indole sPLA2 inhibitor compound.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: August 14, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael Lyle Denney, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
    Patent number: 5849769
    Abstract: A method for treating HIV which comprises a compound of the formula ##STR1## wherein A is ##STR2## and Z.sub.i is O, Se, NR.sup.a or C(R.sup.a).sub.2, andZ.sub.ii is --O or (.dbd.O).sub.2 ;whereinR.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as defined in the specification.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: December 15, 1998
    Assignee: Medivir AB
    Inventors: Peter Thomas Lind, Rolf Noreen, John Michael Morin, Robert John Ternansky